Report Categories
View AllRecent Articles
View All
IKT Inhibikase Therapeutics beats Q4 2025 loss estimates shares post modest gains following earnings release
BCRX BioCryst delivers steep Q4 2025 EPS miss versus consensus estimates yet shares edge higher in todays trading
MYGN Myriad Genetics Q1 earnings miss by 289 percent as EPS decline overshadows flat revenue performance
The fundamentals driving Oculis OCSAW everyone should understand Market Focus 20260506